Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

NCT ID: NCT05415917

Last Updated: 2023-08-22

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 75 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-29
• Study Completion Date: 2025-03-01

Brief Summary

Primary Objectives:

To determine the disease free survival (DFS) for participants treated with post-operative adjuvant chemotherapy, as compared to neoadjuvant therapy alone.

Secondary Objectives:

To determine the clinical efficacy of the study treatment in terms of median overall survival (OS) and median disease free survival (DFS).

To assess the safety and tolerability of the study treatment regimen as measured by the adverse events rates.

To assess the quality of life in patients receiving the study treatment.

Detailed Description

The purpose of the research is to compare the usual treatment approach (chemotherapy followed by surgery) to using chemotherapy followed by surgery and then more chemotherapy. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the lifespan of patients compared to the usual approach. There will be two arms of the study. Arm one will receive treatment with gemcitabine and capecitabine every 28 days for 6 cycles. Arm two be will receive standard of care observation. Participants will be asked to undergo imaging (e.g., CT) and laboratory testing to monitor for disease recurrence. The time in the study will be for 30 months.

Conditions

Pancreatic Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group 1- Gemcitabine and Capecitabine Treatment

Day 1, Day 8, Day 15 • Gemcitabine infused through a vein over 120 minutes

Day 1 - Day 21

• Capecitabine tablets will be taken two times a day; once in the morning and once in the evening. The tablets should not be crushed or split and should be taken with a full glass of water (8 ounces/240 milliliters) within 30 minutes after a meal.

Group Type: EXPERIMENTAL

Gemcitabine and Capecitabine

Intervention Type: DRUG

A chemotherapy cycle will constitute 28 days of treatment:

1. Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle

2. Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle.

Group 2 - Observational

Usual therapy used to treat this type of cancer, chemotherapy plus radiation therapy. If cancer returns during observation, there will be offered standard of care therapy. Follow-up visits will be every three months.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Gemcitabine and Capecitabine

A chemotherapy cycle will constitute 28 days of treatment:

1. Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle

2. Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically and/or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma
• Neoadjuvant chemotherapy (for at least three months) ± chemoradiation followed by R0 surgical resection
• Eastern Cooperative Oncology Group(ECOG) Performance status of PS 0 - 2
• At least 18 years of age
• Adequate bone marrow and organ functions as defined by:

• Absolute neutrophil count ≥ 1000 cells/ μL
• Hemoglobin ≥ 8 g/ dL
• Platelets > 75,000 / μL
• Creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault
• Total bilirubin ≤1.5 ULN
• AST/ ALT < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal
• Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately
• Ability to understand the nature of this study protocol and give written informed consent.
• Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures

Exclusion Criteria

• Receipt of any investigational agents at the time of registration
• Known, untreated brain metastases
• Presence of metastatic disease or malignant ascites on diagnostic imaging
• Grade two or greater peripheral neuropathy
• Presence of any additional active malignancy within the past 3 years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
• Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure (NYHA classification grade III or IV), unstable angina or active arrhythmia
• Major surgery within the 4 weeks prior to initiation of study treatment
• A history of allergy or hypersensitivity to any of the study drugs
• Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study
• Pregnancy
• Severe hepatic impairment
• Participants with known malabsorption

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rutgers, The State University of New Jersey

OTHER

Sponsor Role: lead

Responsible Party

Prateek Gulhati, MD, PhD

Assistant Professor, Department of Gastrointestinal Medical Oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Prateek Gulhati, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Rutgers Cancer Institute of New Jersey

Locations

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Prateek Gulhati, MD, PhD

Role: CONTACT

pat.gulhati@rutgers.edu

732-235-2465

Howard S Hochster, MD

Role: CONTACT

howard.hochster@rutgers.edu

732-235-2465

Facility Contacts

Prateek Gulhati, MD

Role: primary

pat.gulhati@rutgers.edu

732-253-5618

Other Identifiers

Pro2022000669

Identifier Type: OTHER

Identifier Source: secondary_id

CINJ 072206

Identifier Type: -

Identifier Source: org_study_id